Disclaimer: This content is for educational purposes only and is not a substitute for medical advice. This is an FDA-approved prescription medication. Consult your healthcare provider before starting, stopping, or changing any treatment.
What Semaglutide Is and What It's Approved For
Semaglutide is a synthetic GLP-1 receptor agonist — a lab-made version of a gut hormone that helps regulate appetite and glucose. It is available as a weekly injection and a daily oral tablet, both by prescription.
In the United States, semaglutide is FDA-approved for type 2 diabetes (Ozempic injection; Rybelsus oral), chronic weight management in adults and adolescents 12+ who meet criteria (Wegovy), and cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight. A higher-dose Wegovy HD formulation was also approved for weight loss and long-term weight maintenance in certain adults.
This page covers its mechanism, approved formulations, dosing, side effects, and regulatory status.
What Is Semaglutide?
Semaglutide is a synthetic analog of human GLP-1, an incretin hormone released after meals. A small amino acid substitution plus a fatty acid side chain lets it bind albumin and resist rapid breakdown, so the effect lasts about a week and supports weekly dosing.
Class-wise, it sits in the incretin family of GLP-1 receptor agonists. It was built with modern peptide chemistry, not harvested from animal tissue. By design, it is stable in circulation and active at the GLP-1 receptor.
In the United States, semaglutide is FDA-approved under multiple brand names with distinct indications. Ozempic (injection) and Rybelsus (oral) are indicated for type 2 diabetes. Wegovy (injection) is indicated for chronic weight management. The 2024 label expansion added cardiovascular risk reduction for adults with established cardiovascular disease and obesity or overweight. Compounded versions prepared by licensed 503A or 503B pharmacies are legally distinct from these FDA-approved products and are not FDA-approved.
How Semaglutide Works in the Body
Think of semaglutide as a volume knob on your metabolic control network. It binds GLP-1 receptors in the pancreas, brain, and gut, then may influence several metabolic systems.
In the pancreas, it ramps insulin when glucose is high and eases off when glucose is low. That glucose-dependent action means smoother post-meal curves without pushing you into hypoglycemia. It also tamps down glucagon during hyperglycemia, which lowers hepatic glucose output.
In the brain, GLP-1 signaling in the hypothalamus and brainstem reduces appetite and food reward. People notice feeling full sooner and less urge to graze.
In the gut, gastric emptying slows early on, so food leaves the stomach more gradually. That blunts glucose spikes. The gut often adapts over time, while central appetite signaling tends to persist.
Downstream, large randomized trials suggest A1c drops of about 1 to 2 percentage points in type 2 diabetes, substantial average weight loss at obesity doses, and about a 20 percent reduction in major adverse cardiovascular events in defined populations over roughly three years.
Dosing and Administration Essentials
The strategy is slow, steady titration. You build to an effective maintenance dose while keeping gastrointestinal effects tolerable.
Type 2 diabetes (weekly injection)
Typical titration: 0.25 mg weekly for 4 weeks, then 0.5 mg. If additional effect is needed and tolerated, 1 mg, then up to 2 mg. Site rotation (abdomen, thigh, upper arm) reduces local reactions. Same day each week keeps levels steady.
Chronic weight management (weekly injection)
A gradual ramp improves tolerability: 0.25 mg for 4 weeks, then 0.5 mg for 4, 1.0 mg for 4, 1.7 mg for 4, then 2.4 mg as maintenance. Some individuals remain at 1.7 mg if that balance suits their biology.
Type 2 diabetes (oral tablet)
Begin at 3 mg daily for 30 days, then 7 mg. If needed, move to 14 mg. Take on an empty stomach with up to 4 oz (120 mL) of water, then wait 30 minutes before food or other meds. Swallow whole. The absorption enhancer requires that empty-stomach window for reliable uptake.
Weekly injections can be taken any time of day, with or without food, as long as the weekly rhythm is consistent. Cycling is not part of this therapy; when stopped, weight regain was common in trials.
Safety, Side Effects, and Contraindications
Every effective tool has trade-offs. The safety profile is well described across multi-year trials, but individual responses differ.
Gastrointestinal effects are most common. Nausea, early fullness, burping, constipation, or diarrhea cluster around dose increases. This reflects altered gut motility and brain-gut signaling. Symptoms tend to track with meal size and fat load during titration.
Gallbladder issues can occur. Rapid weight loss and bile composition changes increase risk for gallstones. Persistent right upper quadrant pain merits evaluation.
Pancreatitis is rare but serious. Sudden, persistent upper abdominal pain that radiates to the back, often with vomiting, is a red flag. Labels advise avoiding semaglutide in those with a history of pancreatitis and stopping if pancreatitis is suspected.
Kidney function can worsen in the setting of dehydration from prolonged vomiting or diarrhea. The mechanism is volume loss, not direct kidney toxicity. Renal labs are useful if symptoms are significant or baseline kidney disease exists.
There is a boxed warning about thyroid C-cell tumors based on rodent data; human relevance is unclear. It is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN2. New neck masses, hoarseness, or trouble swallowing need attention.
Diabetic retinopathy can transiently worsen if A1c drops quickly. That phenomenon is not unique to semaglutide. People with existing retinopathy often have ophthalmology follow-up as glucose improves.
Pregnancy and breastfeeding require special consideration. It is not recommended during pregnancy, and timing discontinuation before conception matters because of the long half-life. For adolescents, the obesity indication begins at age 12, with attention to growth, nutrition, and mental health.
Longer-term data now include multi-year outcomes, including cardiovascular endpoints and sustained weight trajectories, though lifelong exposure data are still accruing.
Where It Fits Among Peptides: Smart Comparisons
Semaglutide sits among incretin-based therapies. Each option has a distinct fingerprint.
Liraglutide is a daily GLP-1 receptor agonist. It improves glucose and reduces appetite, but average weight loss tends to be smaller and dosing is daily rather than weekly.
Dulaglutide and weekly exenatide are also GLP-1 receptor agonists with weekly dosing. They support glycemic control and weight to varying degrees. Device design and GI tolerability differ by person.
Tirzepatide targets both GIP and GLP-1 receptors. In head-to-head trials, it often produces greater average weight loss and glucose lowering than GLP-1 agents alone, with similar GI trade-offs.
In type 2 diabetes, GLP-1 agents commonly pair with metformin and may be combined with SGLT2 inhibitors when cardiovascular or renal risk reduction is indicated. For weight management, physiology is the stack: muscle contraction moves glucose into cells independent of insulin, and adequate protein intake supports muscle protein synthesis so lean mass is preserved while fat mass falls. Selection depends on the individual's clinical profile, approved indications, and goals discussed with their clinician.
Legal Status and Regulatory Landscape
Semaglutide is a prescription medication with FDA-approved indications for type 2 diabetes (injectable and oral) and chronic weight management (injectable), with specific criteria for use. Labels and delivery devices differ by indication.
Compounded semaglutide is not FDA-approved. Some compounded versions have used salt forms (for example, semaglutide sodium or acetate) that are not the same active ingredient as the approved drug. The FDA reported dosing and sterility concerns and adverse event reports. The national shortage that previously allowed broader compounding exceptions ended in 2025, so standard federal limits apply again (sections 503A and 503B). That means compounding is generally not permitted when an approved product is available and not in shortage.
For athletes, anti-doping rules matter. As of 2025, semaglutide is not on the World Anti-Doping Agency Prohibited List, but GLP-1 receptor agonists are included in certain WADA monitoring activities. Policies evolve by sport and federation. Anyone subject to testing should verify the current WADA List and their federation's requirements, and confirm if a Therapeutic Use Exemption is needed.
Semaglutide is a regulated therapy. Legitimate prescribing and supply chains protect safety.
Summary
Semaglutide is a GLP-1 receptor agonist FDA-approved for type 2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy), and cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight. In clinical trials, it was associated with meaningful A1c reductions, significant weight loss, and fewer major cardiovascular events in defined populations. Most side effects are gastrointestinal. Patients considering this medication should discuss appropriateness, contraindications, and monitoring with a licensed clinician.
Regulatory and Availability Status
- Regulatory Status: FDA-approved for type 2 diabetes (Ozempic injection; Rybelsus oral), chronic weight management (Wegovy), and cardiovascular risk reduction. Wegovy HD higher-dose formulation also approved.
- Research Stage: Approved and marketed; compounded versions lack FDA approval
- Availability: Prescription only
Disclaimer: This content is for educational purposes only and is not a substitute for medical advice. This is an FDA-approved prescription medication. Consult your healthcare provider before starting, stopping, or changing any treatment.
.svg)
.avif)